Clinical trials
Active, not recruiting Phase 1 trials
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
1,949 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2002 | 2 |
| 2004 | 2 |
| 2005 | 1 |
| 2006 | 3 |
| 2007 | 2 |
| 2008 | 6 |
| 2009 | 7 |
| 2010 | 13 |
| 2011 | 14 |
| 2012 | 12 |
| 2013 | 18 |
| 2014 | 36 |
| 2015 | 39 |
| 2016 | 56 |
| 2017 | 81 |
| 2018 | 88 |
| 2019 | 133 |
| 2020 | 138 |
| 2021 | 184 |
| 2022 | 234 |
| 2023 | 256 |
| 2024 | 247 |
| 2025 | 268 |
| 2026 | 109 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Active, not recruiting | 1,949 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| National Cancer Institute (NCI) | 102 |
| M.D. Anderson Cancer Center | 66 |
| Memorial Sloan Kettering Cancer Center | 65 |
| City of Hope Medical Center | 56 |
| AbbVie | 28 |
| Dana-Farber Cancer Institute | 27 |
| Baylor College of Medicine | 26 |
| University of Pennsylvania | 25 |
| Janssen Research & Development, LLC | 24 |
| AstraZeneca | 23 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Carcinoma, Non-Small-Cell Lung | 104 |
| Breast Neoplasms | 92 |
| Neoplasms | 80 |
| Melanoma | 67 |
| Neoplasm Metastasis | 65 |
| Leukemia, Myeloid, Acute | 64 |
| Colorectal Neoplasms | 63 |
| Prostatic Neoplasms | 62 |
| Glioblastoma | 60 |
| Ovarian Neoplasms | 60 |
Trials
Showing 1 to 25 of 1,949. Each trial links to its page on Pharma Observatory.
1,849 more trials match. See them on Pharma Observatory
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.